AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of January ...
The season of Skyrizi continues as the treatment for psoriasis, Crohn’s disease and psoriatic arthritis from AbbVie notched the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands.
AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.
Investor's Business Daily on MSN
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
AbbVie stock popped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback